Navigation Links
XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
Date:7/15/2011

THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. This approval of XGEVA applies to all 27 European Union (EU) member states. The EC also granted XGEVA an additional year of data and market exclusivity in the EU since the indication was considered new for denosumab and based on the significant clinical benefit of XGEVA in comparison with existing therapies.

Bone metastases, the spread of cancer to the bones, are a common and serious concern for patients with advanced cancer and present a burden to the healthcare system. Weakened bones due to metastases can lead to SREs. The primary goal of treatment for bone metastases is to prevent the occurrence of these debilitating and costly SREs.

"Skeletal-related events associated with bone metastases are truly devastating and painful for patients living with cancer, and today's approval of XGEVA marks a real advance," said Professor Ingo J. Diel, M.D., Institute for Gynecological Oncology, SPGO, Mannheim, Germany. "In clinical trials XGEVA demonstrated sustained protection from SREs and also delayed the progression of pain. These factors will make a genuine difference in the lives of patients living with advanced cancer."

The marketing authorization for XGEVA is based on three pivotal, Phase 3 head-to-head trials that evaluated the effectiveness of XGEVA versus zoledronic acid at delaying SREs. The SRE clinical program for XGEVA spanned more than 50 tumor types in over 5,700 patients. In the SRE trials, XGEVA demonstrated a clinically meaningful improvement in preventing SREs compared to zoledronic acid. In these trials, XGEVA was administered every four weeks as a 120 mg subcu
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
2. Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
3. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
4. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
5. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
6. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
7. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
8. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
9. China Botanic Pharmaceutical Granted China Patent for Siberian Ginseng Extraction Process
10. ACT Granted EU Orphan Medicinal Product Designation for hESC-Derived RPE Cells for Treatment of Stargardts Disease
11. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 /PRNewswire/ ... biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for ... need and commercial potential, today announced that it ... shares of its common stock and Series C ... stock.  Funds under the management of QVT Financial ...
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... YORK, Feb. 9, 2012 Just weeks after winning ... behalf of Novartis Pharmaceuticals Sales Representatives, Attorneys from Sanford ... complaint in the U.S. District Court for the Southern ... Sales Representatives and other similarly-situated employees at LEO Pharma ...
... Resource Anesthesia , an anesthesia contract management company based ... its management portfolio. Phil Haynie, MBA, MSN, ... company has added the following facilities to its roster ... -- Hadley, 4601 Martin Luther King Jr. Avenue S.W., ...
Cached Medicine Technology:Leo Pharma Sales Reps File Overtime Class Action in New York Federal Court 2Leo Pharma Sales Reps File Overtime Class Action in New York Federal Court 3Resource Anesthesia Adds Locations Under Management, Announces Addition of HealthStream LearningCenter® 2
(Date:12/24/2014)... (PRWEB) December 25, 2014 Epigenetics finds ... science research, including oncology, drug discovery, developmental biology, and ... emerging as one of the most widely used techniques ... to GLOBOCAN, the prevalence of cancer is rapidly growing ... cases, 8.2 million cancer deaths, and 32.6 million people ...
(Date:12/24/2014)... York, New York (PRWEB) December 24, 2014 ... to mount in a mass tort litigation currently underway ... LLP reports. As of December 24, 2014, court ... the proceeding on behalf of individuals who developed gynecomastia ... its use. Data from the Court indicates that this ...
(Date:12/24/2014)... New York (PRWEB) December 24, 2014 ... http://www.xareltolawsuit2015.com/ ) that allege the blood thinner caused ... has outlined a leadership structure for the proceeding, ... dated December 17th, the Court plans to select ... parties and also plans on appointing a Plaintiffs’ ...
(Date:12/24/2014)... TX (PRWEB) December 25, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. Stivarga is a drug which is used ... drug is orally administered and is also prescribed to ... drug which is FDA approved is a multi-kinase inhibitor ...
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter ... who have abstained from sex for one year will be allowed ... policy that would reverse a 31-year ban on donations from men ... Administration announced Tuesday its intention to release a new draft guidance ... donations from gay men. The FDA is changing its policy ...
Breaking Medicine News(10 mins):Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3
... , Diabetes: A Deeper Look ... , DETROIT, Dec. 3 In the United States, a ... the Detroit Science Center will debut its newest exhibit, Diabetes: A ... about diabetes, diabetes treatment and the role insulin plays in the body. ...
... , WASHINGTON, Dec. 3 The Redwood Gazette ... struggling financially and worried about paying for their medicines. The ... more than 6 million patients find programs providing prescription medicines for ... has access to information on more than 475 patient assistance programs, ...
... in solid organ transplants have been issued with expert advice ... the global H1N1 (swine flu) pandemic. The paper, ... also urges them to stay alert to the significant concerns ... even bird flu (H5N1), to develop into a strain with ...
... compulsive users also feel depressed or anxious when not online ... Chinese adolescents found that teens who are addicted to the ... teens. , The survey of 1,618 students aged 13 ... Guangzhou in Guandong Province found that about 16 percent said ...
... ... of surgical cases on the iPhone or iPod touch. Pop up menu’s and one touch exporting ... provider. , ... I-Surgery , a new iPhone application for surgery, can be used by surgeons, residents, surgical ...
... ... to cheer up children during the holidays with his self-published and illustrated books, “Little ... nationwide. , ... (PRWEB) December 3, 2009 -- Carlton Scott RN , hopes to bring holiday ...
Cached Medicine News:Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 2Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 3Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 4Health News:Transplant infectious disease experts provide pandemic guidance 2Health News:Transplant infectious disease experts provide pandemic guidance 3Health News:Teen Internet Addicts More Likely to Self-Harm: Study 2Health News:Traveling Nurse Cheers up Kids with Handmade Books 2Health News:Traveling Nurse Cheers up Kids with Handmade Books 3
... manufactures slides that are compatible with multichannel ... the number of pipetting steps required to ... on the slides. Ask Immuno Concepts for ... slides. These slide formats are noted with ...
... The ANA and ENA assays ... patients negative for antinuclear antibodies, which ... diseases such as Systemic lupus erythematosus ... disease, progressive systemic sclerosis, scleroderma, polymyositis, ...
... ENA assays can be used to ... antibodies, which are associated with various ... lupus erythematosus (Lupus), Sjgren's syndrome, mixed ... scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
Medicine Products: